122852-69-1 Alosetron HCl AKSci J40177
 
 
Loading Please Wait...
  J40177    
Alosetron HCl
, 98% (HPLC)
 
2,3,4,5-Tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one hydrochloride

Structure N/A

IDENTITY
CAS Number:122852-69-1
MDL Number:MFCD03453647
MF:C17H19ClN4O
MW:330.81
SPECIFICATIONS & PROPERTIES
Purity:98% (HPLC)
Spectra:LCMS, FT-IR, HPLC
Physical Form:Almost white crystalline powder or powder
Melting Point:285-291°C
Long-Term Storage:Store long-term at 2-8°C
UN #:UN2811
Hazard Class:6.1
Packing Group:III

BIOLOGICAL INFO
Solubility:H2O: 5 mg/mL at warmed
Application(s):5-HT3 antagonist
Form:HCl salt

REVIEW

 Alosetron is a potent and selective 5-HT3 receptor antagonist. 5-HT3 receptors are nonselective cation channels that are extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels and the resulting neuronal depolarization affect the regulation of visceral pain, colonic transit and gastrointestinal secretions, processes that relate to the pathophysiology of irritable bowel syndrome (IBS). 5-HT3 receptor antagonists such as alosetron inhibit activation of non-selective cation channels which results in the modulation of serotonin-sensitive GI motor and sensory processes.

REFERENCES
[1]Andresen V, Hollerbach S: Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? Drug Saf. 2004;27(5):283-92.
[2] Camilleri M: Pharmacology and clinical experience with alosetron. Expert Opin Investig Drugs. 2000 Jan;9(1):147-59.
[3] Mayer EA, Bradesi S: Alosetron and irritable bowel syndrome. Expert Opin Pharmacother. 2003 Nov;4(11):2089-98.
[4] Rahimi R, Nikfar S, Abdollahi M: Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther. 2008 May;30(5):884-901.

GHS

Pictograms

Signal Word
Danger

Hazard Statements
H301; H319; H411

Precautionary Statements
P264; P270; P273; P280; P301+P310+P330; P305+P351+P338; P337+P313; P391; P405; P501


Current as of January 18, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Serotonin Antagonists


PubChem